FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

| OMB Number: | 3235-0287 | | | | |
|--------------------------|-----------|--|--|--|--|
| Estimated average burden | | | | | |
| hours per response: | 0.5 | | | | |

| Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 |
|--|
| or Section 30(h) of the Investment Company Act of 1940 |

| | | | or Section 30(n) of the investment Company Act of 1940 | |
|---|---------------|----------------|---|---|
| Name and Address of Reporting Person* <u>Anicetti Vincent R</u> | | Person* | 2. Issuer Name and Ticker or Trading Symbol <u>Coherus BioSciences, Inc.</u> [CHRS] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) |
| (Last) COHERUS BIO 333 TWIN DOI | | | 3. Date of Earliest Transaction (Month/Day/Year) 01/19/2021 | Chief Operating Officer |
| (Street) REDWOOD CITY (City) | CA (State) | 94065 (Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transa Code (8) | | | Acquired (A) or (D) (Instr. 3, 4 and 5) | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|---------------------------------|--|---|------------------------------|---|--------|--|--------------------------|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 01/19/2021 | | М | | 2,500 | A | \$2.5005 | 62,239 ⁽¹⁾ | D | |
| Common Stock | 01/19/2021 | | S ⁽²⁾ | | 2,500 | D | \$17.9408 ⁽³⁾ | 59,739 ⁽¹⁾ | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | | | (0) | | | , | | , i , | | | , | | | | |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|---|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | derivative Securities Beneficially Owned | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option (Right to Buy) | \$2.5005 | 01/19/2021 | | М | | | 2,500 | (4) | 06/30/2024 | Common Stock | 2,500 | \$0.00 | 2,488 | D | |

Explanation of Responses:

1. Includes 52,083 restricted stock units.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

3. The transaction was executed in multiple trades in prices ranging from \$17.76 to \$18.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

4. All of the shares underlying this option are vested and exercisable as of the date hereof.

| | <u>/s/</u>] | lean- | Fred | leric ` | <u>Viret, as</u> |
|--|--------------|-------|------|---------|------------------|
|--|--------------|-------|------|---------|------------------|

Attorney-in-Fact for Vincent R. 01/21/2021

<u>Anicetti</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.